Topas Therapeutics
3 known investors
Topas Therapeutics develops a nanoparticle platform technology to establish immune tolerance in autoimmune and immune-mediated diseases. The company's lead candidate, TPM502, targets liver cells to drive anti-inflammatory immune responses and is in Phase 2b clinical trials for celiac disease.